| Patient | Marcus Aurelius |
|---|---|
| Date of birth | 1973-04-25 |
| Identifiers | MRN HR-AC004-SYN; SSN (made up) 000-04-1213 |
| Document date | 2026-05-12 |
| Author | Octavia Ashworth-Nnamdi, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
New patient visit for chronic epigastric and lower chest pain after meals, poor appetite and poor sleep: cardiac assessment first, review of an opium-containing remedy, and gastroenterology referral for endoscopy [S]
This fictional modern episode addresses the presenting concerns below. [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
3 later historical claims are omitted because they describe events after the index age. See the teaching note.
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| In boyhood (year not recorded) | As a boy, study so hard that it impaired his health (no illness named) | D (CLM-0015) |
| Before the first book of the Meditations, written about 171 to 175 CE | Blood-spitting and giddiness, for which he credits remedies shown to him in dreams (cause not recorded in the cited source) | D (CLM-0008) |
| During his reign (year not recorded) | Frail in body; stomach and chest 'in bad condition'; ate little and only at night; took theriac daily (cause not recorded in the cited source) | D (CLM-0006, CLM-0009) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Opium-containing compounded herbal paste (an electuary of honey, many herbs and poppy, from an overseas supplier; not prescribed and not regulated, so its morphine content is unknown), about a pea-sized amount (roughly 0.5 g) by mouth at bedtime most nights for about six years, and now and then in the morning before a long day | About 0.5 g at bedtime most nights; occasionally a second amount in the morning | Oral route | 2020-05-01 to 2026-06-06 | completed | S |
| Calcium carbonate 500 mg chewable tablet, one or two tablets as needed for heartburn, no more than six a day, until the endoscopy | One or two tablets as needed, at least four hours apart; no more than six a day | Oral route | 2026-05-12 to 2026-05-19 | completed | S |
| Polyethylene glycol 3350 powder, 17 g dissolved in a glass of water by mouth once daily as needed for constipation | 17 g once daily as needed | Oral route | 2026-05-12 | active | S |
| Naloxone 4 mg nasal spray, one spray into one nostril for suspected opioid overdose, repeated in 2 to 3 minutes in the other nostril if there is no response; call 911 | One spray for suspected overdose; repeat every 2 to 3 minutes if needed | Nasal route | 2026-05-12 | active | S |
Positive for the concerns in the history of present illness. Courteous, measured and reflective; mood 'tired, but steady'; no hopelessness or thoughts of self-harm; PHQ-9 8 with item 9 scored 0, and GAD-7 6. No other systems reported as affected in this synthetic episode. [S]
Alert and engaged. Independent in all activities; works full days; tired by evening. [S]
Vital signs recorded on 2026-05-12; see the Vital Signs section. Mental status: Courteous, measured and reflective; mood 'tired, but steady'; no hopelessness or thoughts of self-harm; PHQ-9 8 with item 9 scored 0, and GAD-7 6. The physical examination is limited to the findings relevant to this synthetic episode. [S]
Structured safety assessment: current ideation absent, intent absent, plan absent, access to means reviewed: yes. Outpatient care; the 988 Suicide & Crisis Lifeline; naloxone at home; the remedy kept in a closed container out of others' reach and never taken with alcohol or sleep medicines; review at every visit. [S]
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-05-12 | Body height | 172 | cm | S |
| 2026-05-12 | Body weight | 63 | kg | S |
| 2026-05-12 | Body mass index (BMI) [Ratio] | 21.3 | kg/m2 | S |
| 2026-05-12 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-05-12 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-05-12 | Heart rate | 76 | /min | S |
| 2026-05-12 | Respiratory rate | 14 | /min | S |
| 2026-05-12 | Body temperature | 36.6 | Cel | S |
| 2026-05-12 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-05-12 | Hemoglobin [Mass/volume] in Blood | 14.6 | g/dL | 13.2-17.1 g/dL | Normal | S |
| 2026-05-12 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 90 | fL | 80-100 fL | Normal | S |
| 2026-05-12 | Leukocytes [#/volume] in Blood by Automated count | 6.2 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-05-12 | Platelets [#/volume] in Blood by Automated count | 238 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-05-12 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-05-12 | Potassium [Moles/volume] in Serum or Plasma | 4.3 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-05-12 | Urea nitrogen [Mass/volume] in Serum or Plasma | 14 | mg/dL | 7-20 mg/dL | Normal | S |
| 2026-05-12 | Creatinine [Mass/volume] in Serum or Plasma | 0.95 | mg/dL | 0.7-1.3 mg/dL | Normal | S |
| 2026-05-12 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 96 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-05-12 | Glucose [Mass/volume] in Serum or Plasma | 92 | mg/dL | 70-139 mg/dL | Normal | S |
| 2026-05-12 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 7-55 U/L | Normal | S |
| 2026-05-12 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 8-48 U/L | Normal | S |
| 2026-05-12 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 72 | U/L | 40-129 U/L | Normal | S |
| 2026-05-12 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-05-12 | Albumin [Mass/volume] in Serum or Plasma | 4.1 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-05-12 | Lipase [Enzymatic activity/volume] in Serum or Plasma | 32 | U/L | 13-60 U/L | Normal | S |
| 2026-05-12 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.4 | % | Below 5.7% is normal; 5.7 to 6.4% prediabetes | Normal | S |
| 2026-05-12 | Cholesterol [Mass/volume] in Serum or Plasma | 205 | mg/dL | <=199 mg/dL | High | S |
| 2026-05-12 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 48 | mg/dL | >=40 mg/dL | Normal | S |
| 2026-05-12 | Triglyceride [Mass/volume] in Serum or Plasma | 120 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-05-12 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 133 | mg/dL | <=129 mg/dL | High | S |
| 2026-05-12 | Lipoprotein a [Moles/volume] in Serum or Plasma | 38 | nmol/L | 125 nmol/L or more adds to cardiovascular risk | Normal | S |
| 2026-05-12 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 8 | {score} | S | ||
| 2026-05-12 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 6 | {score} | S | ||
| 2026-05-12 | Total score [AUDIT-C] | 3 | {score} | S |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Burning and pressing pain in the upper abdomen and lower chest after meals, for more than a year and worse over three months, with poor appetite, waking at night with pain and a sour taste, and a 3 kg weight loss; not brought on by exertion; normal ECG; cardiac and peptic causes to be excluded | active | confirmed | R10.13 | S — Synthetic presenting concern at the index visit, superseded by the diagnosis at endoscopy; its pattern echoes the stomach and chest complaints and the pain with food that Dio describes (D). |
| Daily use of an unregulated opium-containing herbal remedy for about six years, for stomach pain and sleep; opioid use disorder criteria not met (one DSM-5-TR criterion, restlessness and poor sleep when he stopped it); expected physiological dependence; constipation and possibly slowed gastric emptying from the opioid | active | confirmed | F11.90 | S — Synthetic modern finding anchored to the theriac he took (D); no opioid use disorder or addiction is attributed to him (the claim is disputed, R). |
| Chronic insomnia disorder for more than a year, with waking from night pain and trouble returning to sleep; Insomnia Severity Index 17 (moderate) | active | confirmed | G47.00 | S — Synthetic modern finding anchored to Galen's account of his sleeplessness without the poppy juice (D, possible). |
| Sustained strain of command: leads a large organization through a long field assignment far from home, with long days and little rest | active | confirmed | Z56.6 | S — Synthetic work strain anchored to his documented years on campaign (D). |
| Constipation from the opioid in his remedy: hard stools every two or three days | active | confirmed | K59.03 | S — Synthetic finding at intake. |